Literature DB >> 11564128

Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II.

J Paysant1, A Rupin, S Simonet, J N Fabiani, T J Verbeuren.   

Abstract

Human urotensin-II (hU-II) is a cyclic peptide recently cloned in humans and present in human cardiac tissue and human arteries. The effects of hU-II were studied on human coronary bypass grafts in vitro. In three out of eight human mammary arteries, and two out of three human radial arteries, hU-II caused contraction; human saphenous veins did not respond to hU-II. When it exists, the contraction slowly develops and has a low-to-moderate intensity. All radial arteries obtained from young healthy non-human primates contracted strongly to hU-II.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564128     DOI: 10.1046/j.1472-8206.2001.00032.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  7 in total

Review 1.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

2.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

3.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

4.  The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.

Authors:  Christopher L Herold; David J Behm; Peter T Buckley; James J Foley; William E Wixted; Henry M Sarau; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

5.  Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.

Authors:  David J Behm; Christopher L Herold; Eliot H Ohlstein; Steven D Knight; Dashyant Dhanak; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

6.  Urotensin-II: a novel systemic hypertensive factor in the cat.

Authors:  David J Behm; Christopher P A Doe; Douglas G Johns; Kristeen Maniscalco; Gerald P Stankus; Alexandra Wibberley; Robert N Willette; Stephen A Douglas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

Review 7.  The role of urotensin II and atherosclerotic risk factors in patients with slow coronary flow.

Authors:  Ömer Şatıroğlu; Murtaza Emre Durakoğlugil; Mustafa Çetin; Yüksel Çiçek; Turan Erdoğan; Hakan Duman
Journal:  Interv Med Appl Sci       Date:  2016-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.